Finally, to confirm the causality of NET-induced IgA loss after stroke in humans, we analyzed the plasma samples (before and 24 h after treatment) of patients treated with standard thrombolysis plus recombinant human DNase-I compared to only thrombolyzed patients adjusted for age and baseline stroke severity in a small-scale clinical trial (https://classic.clinicaltrials.gov/show/NCT04785066). This evidence concerns the gene CD79A and Stroke.